Movement Alert｜CANSINOBIO Intraday Decline 5.21% in Regular Trading, Moderna Slump Triggers Profit-Taking in Vaccine Sector

Market Focus

2 hours ago

On October 8, CANSINOBIO fell 5.21% in regular trading, trading at HK$36.02 with turnover of HK$377 million.

The decline came after US vaccine giant Moderna plunged 8% overnight, with Citigroup downgrading Moderna to sell, triggering negative sentiment transmission across markets that weighed on Hong Kong vaccine and innovative drug stocks.

Having surged during the National Day holiday on expectations around ESMO conference data, CANSINOBIO accumulated substantial gains and faced significant short-term profit-taking pressure. The company's mRNA personalized tumor vaccine developed in partnership with DEPPUSHI BIO remains in early-stage development, leading to increased market caution regarding near-term valuation realization.

The board also noted recent ISO and market updates, with broader healthcare and CXO names under pressure as sector-wide rotation accelerated.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1199783590"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199783590\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199783590?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-08 15:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199783590","market":"us","top_or_hot":-1,"title":"Movement Alert｜CANSINOBIO Intraday Decline 5.21% in Regular Trading, Moderna Slump Triggers Profit-Taking in Vaccine Sector","media":"Market Focus","content":"<p><p>On October 8, CANSINOBIO fell 5.21% in regular trading, trading at HK$36.02 with turnover of HK$377 million.</p><p>The decline came after US vaccine giant Moderna plunged 8% overnight, with Citigroup downgrading Moderna to sell, triggering negative sentiment transmission across markets that weighed on Hong Kong vaccine and innovative drug stocks.</p><p>Having surged during the National Day holiday on expectations around ESMO conference data, CANSINOBIO accumulated substantial gains and faced significant short-term profit-taking pressure. The company's mRNA personalized tumor vaccine developed in partnership with DEPPUSHI BIO remains in early-stage development, leading to increased market caution regarding near-term valuation realization.</p><p>The board also noted recent ISO and market updates, with broader healthcare and CXO names under pressure as sector-wide rotation accelerated.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CANSINOBIO Intraday Decline 5.21% in Regular Trading, Moderna Slump Triggers Profit-Taking in Vaccine Sector</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CANSINOBIO Intraday Decline 5.21% in Regular Trading, Moderna Slump Triggers Profit-Taking in Vaccine Sector\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-08 15:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 8, CANSINOBIO fell 5.21% in regular trading, trading at HK$36.02 with turnover of HK$377 million.</p><p>The decline came after US vaccine giant Moderna plunged 8% overnight, with Citigroup downgrading Moderna to sell, triggering negative sentiment transmission across markets that weighed on Hong Kong vaccine and innovative drug stocks.</p><p>Having surged during the National Day holiday on expectations around ESMO conference data, CANSINOBIO accumulated substantial gains and faced significant short-term profit-taking pressure. The company's mRNA personalized tumor vaccine developed in partnership with DEPPUSHI BIO remains in early-stage development, leading to increased market caution regarding near-term valuation realization.</p><p>The board also noted recent ISO and market updates, with broader healthcare and CXO names under pressure as sector-wide rotation accelerated.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1199783590","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199783590","pubTimestamp":1791444476,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 8, CANSINOBIO fell 5.21% in regular trading, trading at HK$36.02 with turnover of HK$377 million.The decline came after US vaccine giant Moderna plunged 8% overnight, with Citigroup...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"走势提醒|康希诺生物常规交易盘中下跌5.21%，Moderna暴跌引发疫苗板块获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"On October 8, CANSINOBIO fell 5.21% in regular trading, trading at HK$36.02 with turnover of HK$377 million.The decline came after US vaccine giant Moderna plunged 8% overnight, with Citigroup downgrading Moderna to sell, triggering negative sentiment transmission across markets that weighed on Hong Kong vaccine and innovative drug stocks.Having surged during the National Day holiday on expectations around ESMO conference data, CANSINOBIO accumulated substantial gains and faced significant short-term profit-taking pressure. The company's mRNA personalized tumor vaccine developed in partnership with DEPPUSHI BIO remains in early-stage development, leading to increased market caution regarding near-term valuation realization.The board also noted recent ISO and market updates, with broader healthcare and CXO names under pressure as sector-wide rotation accelerated.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}